Trial · NCT01145183
Pharmacogenetics of Doxazosin for Cocaine Dependence
NCT01145183, Phase 2, Completed, Baylor College of Medicine; results first posted 2019-07-22
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pharmacogenetics of Doxazosin for Cocaine Dependence. Trials, record NCT01145183. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01145183
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pharmacogenetics of Doxazosin for Cocaine Dependence
- NCT number
- NCT01145183
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 96 participants, actual
- Lead sponsor
- Baylor College of Medicine
- Conditions
- Cocaine Dependence
- Interventions
- Doxazosin, Placebo
- First posted
- 2010-06-16
- Last updated
- 2019-07-22
- Results first posted
- 2019-07-22
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Cocaine Positive Urine Toxicology | 2 weeks blocks throughout study | Cocaine positive urines |
| Secondary | Adverse Events | Pre- and post study medication | Adverse effects were closely monitored during each clinic visit throughout this trial. Vital signs including blood pressure (both pre-medication and post-medication) were measured and documented as were concomitant medications. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Cocaine Positive Urine Toxicology | 2 weeks blocks throughout study | percentage of positive urines | NUMBER | |
| SECONDARY | Adverse Events | Pre- and post study medication | events | NUMBER |
Source ClinicalTrials.gov
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Cocaine Positive Urine Toxicology | Doxazosin (AA Genotype) | Weeks 1-2 | 88.6 | percentage of positive urines | |
| Percentage of Cocaine Positive Urine Toxicology | Doxazosin (AT/TT Genotype) | Weeks 1-2 | 85.6 | percentage of positive urines | |
| Percentage of Cocaine Positive Urine Toxicology | Placebo (AA Genotype) | Weeks 1-2 | 75.7 | percentage of positive urines | |
| Percentage of Cocaine Positive Urine Toxicology | Placebo (AT/TT Genotype) | Weeks 1-2 | 75.9 | percentage of positive urines | |
| Percentage of Cocaine Positive Urine Toxicology | Doxazosin (AA Genotype) | Weeks 3-4 | 88.6 | percentage of positive urines | |
| Percentage of Cocaine Positive Urine Toxicology | Doxazosin (AT/TT Genotype) | Weeks 3-4 | 84.7 | percentage of positive urines | |
| Percentage of Cocaine Positive Urine Toxicology | Placebo (AA Genotype) | Weeks 3-4 | 82.8 | percentage of positive urines | |
| Percentage of Cocaine Positive Urine Toxicology | Placebo (AT/TT Genotype) | Weeks 3-4 | 84.7 | percentage of positive urines | |
| Percentage of Cocaine Positive Urine Toxicology | Doxazosin (AA Genotype) | Weeks 5-6 | 84.9 | percentage of positive urines | |
| Percentage of Cocaine Positive Urine Toxicology | Doxazosin (AT/TT Genotype) | Weeks 5-6 | 68.0 | percentage of positive urines |
1 to 10 of 26Source ClinicalTrials.gov
See all 26 results by groupParticipant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Doxazosin (AA Genotype) | 21 | |
| Overall Study | STARTED | Doxazosin (AT/TT Genotype) | 26 | |
| Overall Study | STARTED | Placebo (AA Genotype) | 19 | |
| Overall Study | STARTED | Placebo (AT/TT Genotype) | 10 | |
| Overall Study | COMPLETED | Doxazosin (AA Genotype) | 21 | |
| Overall Study | COMPLETED | Doxazosin (AT/TT Genotype) | 26 | |
| Overall Study | COMPLETED | Placebo (AA Genotype) | 19 | |
| Overall Study | COMPLETED | Placebo (AT/TT Genotype) | 10 | |
| Overall Study | NOT COMPLETED | Doxazosin (AA Genotype) | 0 | |
| Overall Study | NOT COMPLETED | Doxazosin (AT/TT Genotype) | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Doxazosin | 0 | 47 |
| Total, all-cause mortality | Placebo | 0 | 29 |
| Total, other adverse events | Doxazosin | 0 | 47 |
| Total, other adverse events | Placebo | 0 | 29 |
| Total, serious adverse events | Doxazosin | 0 | 47 |
| Total, serious adverse events | Placebo | 0 | 29 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P50DA018197 | Stimulant Pharmacotherapy: Noradrenergic Targets | KOSTEN, THOMAS RICHARD | BAYLOR COLLEGE OF MEDICINE | NATIONAL INSTITUTE ON DRUG ABUSE | 2004 to 2013 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Doxazosin vs Placebo: deaths from any cause | Trial comparisons |
| Doxazosin vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01145183
GET https://conductscience.org/api/trials/v1/NCT01145183/results?page=2